- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05118256
Pirfenidone for the Reduction of Metabolic, Inflammatory and Fibrogenic Activity in Complicated Silicosis
An Open, Randomised, Controlled and Unicenter Clinical Trial to Assess the Efficiency of Pirfenidone for the Reduction of Pulmonary Metabolic, Inflammatory and Fibrogenic Activity in Patients With Silicosis Due to Artificial Stone and PMF
Study Overview
Status
Intervention / Treatment
Detailed Description
Hypothesis: Pirfenidone reduces pulmonary metabolic activity in patients with Progressive Massive Fibrosis (PMF).
Objetives:
Main objetive: To evaluate the efficacy of pirfenidone in reducing pulmonary metabolic activity quantified by PET-CT Scan (F-FDG) in patients with Progressive Massive Fibrosis (PMF).
Secundary objetives:
- To evaluate the efficacy of pirfenidone in reducing pulmonary inflammatory and fibrogenic activity in patients with Progressive Massive Fibrosis (PMF), quantified by cell biomarkers, and the relation with the pulmonary metabolic activity.
- To assess changes brought about by pirfenidone in the different cells biomarkers patterns and metabolic activity resulted by PET/TC with 18-FDG
- To assess radiological changes in HRCT (High Resolution Computed Tomography) that occur after administration of pirfenidone and the relation with biomarkers and with 18F FDG acquisition.
- To assess wheter administration of pirfenidone generates changes on standard funtional respiratory explorations, and the relation with inflammatory and metabolic activity. 5. To assess clinical changes (if any) and safety of pirfenidone after administration to patients with PMF.
Methodology: An Open, Randomised, Controlled, 2 arms and Unicenter Clinical Trial to Assess the Efficiency of Pirfenidone for the Reduction of Pulmonary Metabolic, Inflammatory and Fibrogenic Activity in Patients With Silicosis Due to Artificial Stone and PMF.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Laura Quintana, phD
- Phone Number: +34 639390856
- Email: laura.quintana@inibica.es
Study Locations
-
-
-
Cadiz, Spain, 11009
- Recruiting
- Antonio León Jiménez
-
Contact:
- Antonio León Jiménez, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 1. Age over 18 years and under 65.
- 2. Man with a diagnosis of silicosis in the form of PMF by lung or lymph node biopsy, or by radiological criteria.
- 3. History of exposure to silica in work with artificial stone for at least 5 years.
- 4. Patients capable of consenting to their participation in the study by providing written informed consent, or, if they are not trained, through a legal repressentative.
Exclusion Criteria:
- 1. Participation in another clinical trial in the 6 months prior to the start of participation in this study.
- 2. Hypersensitivity to any of the components of pirfenidone.
- 3. Biological or farmacological treatment for any other disease or condition related to silicosis or PMF. Exception: prednisona (or equivalent) dose 20mg per day or lower.
- 4. Concomitant treatment with a drug that can causes pirfenidone interactions: Cytotoxic drugs, immunosuppressants, cytokine modulators including but not limited to azathioprine, bosentan, ambrisentan, cyclophosphramide, cyclosporine, etarnecept, iloprost, infliximab, leukotriene antagonists, methotrexate, mycophenolate , tacrolimus, montelukast, tetrathiomolybdate, TNF-alpha inhibitors, imatinib mesylate, interferon gamma 1-beta, and tyrosine kinase inhibitors. Strong CYP1A2 inhibitors (eg fluvoxamine, enoxacin), P-glycoprotein or CYP3A4 inhibitors (eg Ketoconazole, erythromycin), or their inducers (eg rifampicin, carbamazepine, phenytoin). Other moderate CYP1A2 inhibitors (eg amiodarone or propafenone) which will also be prohibited. Any investigational therapy in an active clinical trial. Grapefruit juice.
- 5. Active infectious disease.
- 6. Any pathology that may condition the evolution of respiratory diseases, including cancer, HIV, HBV, HCV, liver cirrhosis, liver failure, severe kidney failure or any other that in the opinion of the investigator may interfere with the results of the study.
- 7. Active smoking.
- 8. Laboratory test abnormalities at screening timepoint - Total bilirrubin >2 ULN - AST/SGOT or ALT/SGPT > 2.5 ULN - Alkaline phosphatase >3.0 ULN - Creatinine clearance <40 mL/min (Cockcroft-Gault).
- 9. Concomitant treatments that may cause serious digestive events.
- 10. Digestive surgery or similar procedures that may cause digestive intolerances.
- 11. Not availability to complete all the trial visits.
- 12. Angiodema
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: No intervention - standard of care
A group of patients with PMF will be treated per standard of care on site
|
|
Experimental: Experimental - Pirfenidone plus standard of care
A group of patients with PMF will be treated with pirfenidone plus standard of care on site
|
Patients will be treated with pirfenidone (oral tablets) during 6 months
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Metabolic pulmonary activity assessed by PET-CT Scan (18 FFDG)
Time Frame: baseline (day 1), month 6, month 12
|
Metabolic pulmonary activity assessed by PET-CT Scan (18 FFDG) in patients treated with pirfenidone vs control patients.
The variables will be analyzed in lung and mediastinum independently and the measurement of the metabolic response will be based on the standardized uptake value (SUV) at its maximum (SUVmax) and mean (SUVmean) values.
|
baseline (day 1), month 6, month 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cell biomarkers in peripheral blood: - Pro/anti fibrotic and pro/anti inflammatory biomarkers
Time Frame: baseline (day 1), month 3, month 6, month 9, month 12
|
Pro/anti fibrotic and pro/anti inflammatory biomarkers: cytokines (IL-1α, IL-1β, IL-1RA, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17, IL-18, IP-10, TGF-β, TNF-α, IFN-γ, MIP-1α, MIP-1β, MCP-1, PDGF, bFGF, MMP1, -2, -7, -9, -10).
Immunological biomarkers: CD45, CD45RO, CD45RA, CD3, CD4, CD8, CD19, CD27, CD56, CD126, CD25, INF-γ, IL-4, FoxP3, CD196 y CD161 Note: There are no previous studies in patients with artificial stone silicosis in which they have analyzed the indicated biomarkers.
This is a comprehensive preliminary analysis of biomarkers and we want to correlate the obtained values with the results derived from PET-CT in both groups of patients in the trial.
|
baseline (day 1), month 3, month 6, month 9, month 12
|
Number of adverse events (AE) and adverse reactions (AR), of serious adverse events (SAE) and serious and unexpected adverse reactions (SUSAR).
Time Frame: baseline (day 1), month 3, month 6, month 9, month 12
|
Number of adverse events (AE) and adverse reactions (AR), of serious adverse events (SAE) and serious and unexpected adverse reactions (SUSAR).
|
baseline (day 1), month 3, month 6, month 9, month 12
|
Respiratory symptoms (cough, expectoration and dyspnea) and quality of life related to health using the EQ-5D 5L test.
Time Frame: baseline (day 1), month 3, month 6, month 9, month 12
|
Respiratory symptoms (cough, expectoration and dyspnea) and quality of life related to health using the EQ-5D 5L test.
|
baseline (day 1), month 3, month 6, month 9, month 12
|
Respiratory function variables
Time Frame: baseline (day 1), month 3, month 6, month 9 and month 12
|
Forced Vital Capacity (FVC), Forced Expiratory Volume in the first second, ratio Forced Expiratory in the first second / Forced Vital Capacity and Diffusing Capacity of the lungs for carbon monoxide, obtained through standardized respiratory function tests.
|
baseline (day 1), month 3, month 6, month 9 and month 12
|
Radiological categorization by chest radiology and by High Resolution Computed Tomography, following the International Classification of High-resolution Computed Tomography for Occupational and Environmental Respiratory Diseases (ICOERD)
Time Frame: baseline (day 1), month 6, month 12
|
Radiological categorization by chest radiology and by High Resolution Computed Tomography, following the International Classification of High-resolution Computed Tomography for Occupational and Environmental Respiratory Diseases (ICOERD)
|
baseline (day 1), month 6, month 12
|
Collaborators and Investigators
Investigators
- Principal Investigator: Antonio León Jiménez, MD, Fundación Cádiz- INIBICA
- Principal Investigator: Antonio Campos Caro, phD, Fundación Cádiz- INIBICA
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Lung Diseases
- Occupational Diseases
- Pneumoconiosis
- Lung Diseases, Interstitial
- Lung Injury
- Silicosis
- Physiological Effects of Drugs
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antineoplastic Agents
- Pirfenidone
Other Study ID Numbers
- FUN-PIR-2020-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Silicosis
-
Universidade Federal do Rio de JaneiroMinistry of Health, Brazil; National Research Council, Brazil; Ministry of Science...CompletedChronic and Accelerated SilicosisBrazil
-
Huashan HospitalWenling No.1 People's Hospital, ChinaUnknownSilicosis TuberculosisChina
-
Chinese University of Hong KongCompleted
-
National Heart and Lung InstituteKibong'oto Infectious Disease Hospital, TanzaniaRecruitingTuberculosis | Silicosis | Silicosis; With TuberculosisTanzania
-
The University of QueenslandThe Alfred; Royal Prince Alfred Hospital, Sydney, Australia; The Prince Charles... and other collaboratorsRecruiting
-
The University of QueenslandNot yet recruiting
-
Tel-Aviv Sourasky Medical CenterRabin Medical CenterUnknown
-
Tel-Aviv Sourasky Medical CenterRabin Medical CenterUnknown
-
Johns Hopkins UniversityDuke University; National Institutes of Health (NIH); Fogarty International Center... and other collaboratorsRecruiting
Clinical Trials on Pirfenidone Oral Tablet
-
Blade TherapeuticsCompletedDrug Drug InteractionUnited States
-
EstetraICON Clinical ResearchCompletedVasomotor Symptoms | Menopausal SymptomsUnited States, Canada
-
University of Alabama at BirminghamMayo ClinicRecruiting
-
EicOsis Human Health Inc.RecruitingHealthy SubjectsNew Zealand
-
Cara Therapeutics, Inc.CompletedChronic Kidney Diseases | PruritusUnited States
-
Harmony Biosciences, LLCActive, not recruitingMyotonic Dystrophy 1 | Excessive Daytime SleepinessUnited States, Canada
-
Syntrix Biosystems, Inc.National Institute on Drug Abuse (NIDA); DF/Net ResearchCompletedDiabetic Neuropathies | Neuropathic Pain | Pain, ChronicUnited States
-
Fulcrum TherapeuticsTerminated
-
EicOsis Human Health Inc.CompletedHealthy AdultsUnited States
-
Baylor Research InstituteNot yet recruitingBreast Cancer | Metastatic Triple-Negative Breast CarcinomaUnited States